LuVaCs Leiden

Lupus-, Vasculitis-, Complement mediated Systemic diseases (LuVaCs) Center of Expertise

[burgerinitiatief 2MH - donorwet @2Miljoen]

❤️ het gaat echt #orgaandonatie. Dit jaar wordt het allerbeste ooit. Het kan niet anders dan dat de nieuwe #donorwet werkt 😊. @eurotransplant cijfers nov 2022 tov 2021 https://t.co/TDCS6e9Vto

[LuVaCs Leiden @LuvacsL]

Reminds me of the way we teach our MDs and PhDs to care for patients with complex, systemic autoimmune diseases @LuvacsLeiden @LUMC_Leiden #nephrology #aav #lupus #complement #glomerulonephritis

[Peter Grayson @petercgrayson]

They are finally out! 2022 ACR/EULAR Classification Criteria for Giant Cell Arteritis and Takayasu's Arteritis!!!!

https://t.co/0JaLnvtmfh

https://t.co/0guQEWySYt

[burgerinitiatief 2MH - donorwet @2Miljoen]

❤️❤️❤️ het gaat GOED met #orgaandonatie in Nederland!! Wachtlijst neemt eindelijk af. Aantal donoren blijft ook dit jaar toenemen #donorwet > het aantal postmortale transplantaties daardoor neemt flink toe😀 & het # donaties bij leven ook📈#eurotransplant https://t.co/TDCS6eatiW

[ASN Publications @asnpublications]

Belimumab, a recombinant, human IgG1λ mAb, has been shown to improve kidney outcomes in patients with active lupus nephritis. This 28-week open-label extension of the BLISS-LN study assessed belimumab’s safety and efficacy https://t.co/G9wcnaVQ60

@BradRovin @LUMC_Leiden @LuvacsL

[LuVaCs Leiden @LuvacsL]

Fantastic to see Ton Rabelink presenting @ASNKidney on spatial metabolomics @LUMC_Leiden @LuvacsL #nephrology #Nephpearls #science

[LuVaCs Leiden @LuvacsL]

@AKronbichler @FrontiersIn @MDPIOpenAccess We should stop publishing in Frontiers journals. There are enough good peer-reviewed journals related to scientific societies. At least part of the financial gain drains back to science

[Pankti Mehta @PanktiMehta24]

📝A great compilation of newer treatment options for #Lupus Nephritis by a senior and friend! @SayaliBThakare

#SLE #RheumTwitter #MedTwitter #MedEd

https://t.co/S8QqGGOdi6

[Trinity Kidneys @THKC1]

When you are a short arse and flanked by your tall @_ERNRITA colleagues 😂

Wonderful celebration of the career of Carine Wouters in @leuvenresearch (proudly wearing my @imperialcollege plumage).

[EURORDIS-Rare Diseases Europe @eurordis]

In February, the French Presidency held a Ministerial Conference where high-level representatives expressed their support for a European Action Plan on Rare Diseases. The upcoming Czech Expert Conference will define how this could be achieved.

Read more: https://t.co/inHEVHmSSo

[UNDERSTAND AAV @Understandaav]

With patient-friendly language and simplified science, the Dialogue Tool helps make all things AAV understandable for your patients, meaning they can get the best outcomes from appointments. Take a look today at: https://t.co/TOVJpUUgf9
#AAV #ANCA #vasculitis #raredisease

[Miranda van Tilburg @DrvanTilburg]

Previous PhD student sent this to me and I can't stop laughing.

[Brad H Rovin @BradRovin]

#IgANTreatment Great news for patients and docs. The data from the NefIgArd trial that led to accelerated approval of Nefecon for the treatment of IgAN just out in Kidney International on line. First of many new therapies for IgAN!🤞https://t.co/Tq8LACpCjq

[Andreas Kronbichler @AKronbichler]

What a great day at the EUVAS22 @EUVAS19 meeting in Florence; Apart from technical issues (great view from the moderator perspective)! Moving words by @stephenmcadoo to honour Prof Justin Mason!

[LuVaCs Leiden @LuvacsL]

Cyclophoshamide and Rituximab are successfully the standard of care for patients with active #ANCA-associated #vasculitis. Is combining both better?
Read about our endevour to investigate this in the investigator-initiated randomized ENDURRANCE trial in https://t.co/BnOzmqfC2z

[LuVaCs Leiden @LuvacsL]

By far the best way to end a very successful @SLEuroSociety lupus meeting i Stockholm.I hope to meet all international colleagues and friends soon again

[Ahmed Marcouch @ahmedmarcouch]

Ridder Menno Loos te Arnhem, van harte gefeliciteerd met de enorm eervolle onderscheiding tot Ridder in de Orde van Oranje-Nassau. Eerlijk verdiend, als initiatiefnemer tot de nieuwe wijze van donorregistratie.

[LuVaCs Leiden @LuvacsL]

Today we will present @SLEURO the results of the AURORA-2 study which investigated safety of 3-year long-term treatment with voclosporin versus placebo in #lupus nephritis patients...and obviously looked at prevention of kidney damage. Be there at 11AM CET
https://t.co/sZaeCWwc2G

[LuVaCs Leiden @LuvacsL]

@SLEURO we shared our results on a new mechanism of #belimumab in #SLE patients: initiation of belimumab leads to a disruption of memory B-cell trafficking resulting in an accumulation in peripheral blood of patients...ready to be targeted. https://t.co/sZaeCWwc2G

[LuVaCs Leiden @LuvacsL]

Excited to attend the European Lupus Meeting in Stockholm
https://t.co/t7fIUF5OPT
#SLE #Lupus